Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Iris color changes less in eyes treated with unoprostone
Orlando-The incidence of iris hyperpigmentation associated with unoprostone isopropyl ophthalmic solution 0.15% (Rescula, Novartis) was about 1% in two long-term studies, a rate that compares favorably with the incidence of 10% to 20% associated with latanoprost ophthalmic solution (Xalatan, Pharma-cia) in similar patient populations, reported Bernard E. McCarey, PhD.
Related Videos
Related Content
